Immunotherapy for Glioblastoma
Glioblastoma research has over the past decade has yielded few advances. David Reardon, MD, shares his insights about the current and emerging immuniotherapy treatment landscape for glioblastoma.
Dr. Reardon discloses the following relationships:
Research support (DFCI): Acerta Phamaceuticals; Agenus; Celldex; EMD Serono; Incyte; Inovio; Midatech; Omniox; Tragara
Advisory/consultation (self): Abbvie; Advantagene; Amgen; Agenus; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Deciphera; EMD Serono; FirstWord Expert Panel; Genenta Science; Genentech/Roche; Inovio; Jeffries LLC; Kiyatec; Medicenna; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; RDD Pharma; Regeneron; Stemline; Syndax Pharmaceuticals; Taiho Oncology, Inc.
Honoraria (self): Abbvie; Advantagene; Agenus; Bristol-Myers Squibb; Celldex; California Institute of Regenerative Medicine; EMD Serono; Genentech/Roche; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc.
Speaker: Cancer Research Institute; Institute for International Medicine (INMED)